148 related articles for article (PubMed ID: 21441959)
21. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
22. Early identification and management of graft failure after unrelated cord blood transplantation.
Chan KW; Grimley MS; Taylor C; Wall DA
Bone Marrow Transplant; 2008 Jul; 42(1):35-41. PubMed ID: 18332909
[TBL] [Abstract][Full Text] [Related]
23. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
24. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
27. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
28. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
[TBL] [Abstract][Full Text] [Related]
29. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
[TBL] [Abstract][Full Text] [Related]
32. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
33. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study.
Ogata M; Satou T; Kadota J; Saito N; Yoshida T; Okumura H; Ueki T; Nagafuji K; Kako S; Uoshima N; Tsudo M; Itamura H; Fukuda T
Clin Infect Dis; 2013 Sep; 57(5):671-81. PubMed ID: 23723198
[TBL] [Abstract][Full Text] [Related]
34. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases.
Sawada A; Inoue M; Koyama-Sato M; Kondo O; Yamada K; Shimizu M; Isaka K; Kimoto T; Kikuchi H; Tokimasa S; Yasui M; Kawa K
Biol Blood Marrow Transplant; 2014 Feb; 20(2):214-21. PubMed ID: 24188918
[TBL] [Abstract][Full Text] [Related]
35. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source.
Chevallier P; Hebia-Fellah I; Planche L; Guillaume T; Bressolette-Bodin C; Coste-Burel M; Rialland F; Mohty M; Imbert-Marcille BM
Bone Marrow Transplant; 2010 Jul; 45(7):1204-11. PubMed ID: 19935727
[TBL] [Abstract][Full Text] [Related]
36. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.
Liu Q; Xuan L; Liu H; Huang F; Zhou H; Fan Z; Zhao K; Wu M; Xu L; Zhai X; Zhang F; Liu C; Sun J; Huang X
Am J Hematol; 2013 Jul; 88(7):550-5. PubMed ID: 23564232
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
38. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation.
Mori Y; Miyamoto T; Nagafuji K; Kamezaki K; Yamamoto A; Saito N; Kato K; Takenaka K; Iwasaki H; Harada N; Abe Y; Teshima T; Akashi K
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1596-602. PubMed ID: 20685258
[TBL] [Abstract][Full Text] [Related]
39. Disseminated tuberculosis following reduced-intensity cord blood transplantation for adult patients with hematological diseases.
Maeda T; Kusumi E; Kami M; Kawabata M; Le Pavoux A; Hara S; Chizuka A; Murashige N; Tanimoto TE; Matsumura T; Yuji K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S;
Bone Marrow Transplant; 2005 Jan; 35(1):91-7. PubMed ID: 15516933
[TBL] [Abstract][Full Text] [Related]
40. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.
Sanz J; Arango M; Senent L; Jarque I; Montesinos P; Sempere A; Lorenzo I; Martín G; Moscardó F; Mayordomo E; Salavert M; Cañigral C; Boluda B; Salazar C; López-Hontangas JL; Sanz MA; Sanz GF
Bone Marrow Transplant; 2014 Mar; 49(3):397-402. PubMed ID: 24292521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
